Total Payments
$8,001
2024 Payments
$165.04
Companies
61
Transactions
504
Medicare Patients
28,149
Medicare Billing
$7.1M
Payment Breakdown by Category
Food & Beverage$6,983 (87.3%)
Education$970.67 (12.1%)
Gifts$48.00 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,983 | 483 | 87.3% |
| Education | $970.67 | 20 | 12.1% |
| Gift | $48.00 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $731.31 | 37 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $651.06 | 44 | $0 (2022) |
| PFIZER INC. | $587.76 | 72 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $561.47 | 42 | $0 (2023) |
| Amgen Inc. | $558.70 | 40 | $0 (2023) |
| Genentech USA, Inc. | $509.88 | 33 | $0 (2023) |
| Merck Sharp & Dohme LLC | $444.37 | 28 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $379.02 | 16 | $0 (2023) |
| Astellas Pharma US Inc | $291.93 | 12 | $0 (2024) |
| Seagen Inc. | $276.16 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $165.04 | 4 | Astellas Pharma US Inc ($165.04) |
| 2023 | $686.70 | 29 | Merck Sharp & Dohme LLC ($110.15) |
| 2022 | $2,074 | 93 | Amgen Inc. ($217.43) |
| 2021 | $161.93 | 9 | E.R. Squibb & Sons, L.L.C. ($62.14) |
| 2020 | $411.36 | 21 | Seagen Inc. ($95.00) |
| 2019 | $1,671 | 111 | AstraZeneca Pharmaceuticals LP ($214.18) |
| 2018 | $1,331 | 104 | PFIZER INC. ($232.04) |
| 2017 | $1,501 | 133 | Janssen Biotech, Inc. ($199.72) |
All Payment Transactions
504 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $98.00 | General |
| 01/23/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Oncology | ||||||
| 08/02/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $69.09 | General |
| Category: ONCOLOGY | ||||||
| 03/10/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $20.29 | General |
| Category: Oncology | ||||||
| 03/08/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.94 | General |
| Category: Hematology | ||||||
| 03/07/2023 | Amgen Inc. | Nplate (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Hematology | ||||||
| 03/06/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Hematology | ||||||
| 03/06/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $13.18 | General |
| 02/28/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.36 | General |
| Category: Hematology/Oncology | ||||||
| 02/23/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Education | In-kind items and services | $79.00 | General |
| Category: ONC | ||||||
| 02/22/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: ONC | ||||||
| 02/10/2023 | Jazz Pharmaceuticals Inc. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/08/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Oncology | ||||||
| 02/02/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Oncology | ||||||
| 01/31/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Oncology | ||||||
| 01/30/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 01/27/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $34.84 | General |
| 01/25/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Oncology | ||||||
| 01/24/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.42 | General |
| Category: Iron Deficiency Anemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 76 | 5,912 | 186,913 | $5.9M | $990,473 |
| 2022 | 87 | 6,786 | 211,162 | $9.1M | $1.8M |
| 2021 | 84 | 7,199 | 244,579 | $8.4M | $1.7M |
| 2020 | 91 | 8,252 | 316,654 | $11.9M | $2.6M |
Total Patients
28,149
Total Services
959,308
Medicare Billing
$7.1M
Procedure Codes
338
All Medicare Procedures & Services
338 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 8,000 | $1.2M | $344,057 | 29.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 29 | 6,960 | $389,760 | $128,367 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 304 | 676 | $212,264 | $62,043 | 29.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 27 | 22,485 | $269,820 | $53,488 | 19.8% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 16 | 468 | $473,148 | $44,479 | 9.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 110 | 358 | $241,292 | $33,584 | 13.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 91 | 76,500 | $382,500 | $30,616 | 8.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 24 | 24 | $162,000 | $25,767 | 15.9% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 1,060 | $243,800 | $24,197 | 9.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 111 | 126 | $376,614 | $19,722 | 5.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 239 | 297 | $66,231 | $18,223 | 27.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 20 | 114 | $67,374 | $14,178 | 21.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 408 | 1,107 | $91,881 | $11,431 | 12.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 12,000 | $48,000 | $10,625 | 22.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 188 | $70,876 | $9,626 | 13.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 411 | 1,235 | $76,570 | $9,379 | 12.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 23 | 23 | $21,298 | $9,352 | 43.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 389 | 1,101 | $28,626 | $9,248 | 32.3% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 158 | 180 | $409,140 | $9,056 | 2.2% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 14 | 45 | $30,555 | $8,760 | 28.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 97 | 189 | $64,260 | $8,555 | 13.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $35,508 | $7,724 | 21.8% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 13 | 20,200 | $181,800 | $6,908 | 3.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 88 | 318 | $47,700 | $6,778 | 14.2% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 229 | 440 | $52,360 | $6,490 | 12.4% |
About Dr. Patrick Gomez, MD
Dr. Patrick Gomez, MD is a Hematology & Oncology healthcare provider based in Bloomington, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1972640134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Gomez, MD has received a total of $8,001 in payments from pharmaceutical and medical device companies, with $165.04 received in 2024. These payments were reported across 504 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($6,983).
As a Medicare-enrolled provider, Gomez has provided services to 28,149 Medicare beneficiaries, totaling 959,308 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 338 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Bloomington, IL
- Active Since 01/30/2007
- Last Updated 09/30/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972640134
Products in Payments
- IMBRUVICA (Drug) $389.77
- KEYTRUDA (Biological) $368.48
- OPDIVO (Biological) $324.84
- DARZALEX (Biological) $191.12
- CALQUENCE (Drug) $179.56
- XTANDI (Drug) $178.60
- Neulasta (Biological) $174.69
- VENCLEXTA (Biological) $159.89
- Pomalyst (Drug) $149.35
- JAKAFI (Drug) $133.88
- XALKORI (Drug) $111.15
- ELIQUIS (Drug) $109.18
- SUTENT (Drug) $106.96
- Trodelvy (Drug) $105.68
- KISQALI (Drug) $97.23
- CHANTIX (Drug) $96.36
- IBRANCE (Drug) $96.33
- Cabometyx (Drug) $94.42
- Endari (Drug) $92.25
- TROKENDI XR (Drug) $89.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.